Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Lifescapes System in Post-stroke Hand Recovery

20 agosto 2026 aggiornato da: National University Hospital, Singapore

Effectiveness and Feasibility of a Brain-computer Interface Based Neurofeedback System With Reduced Therapist Supervision for Hand Motor Recovery in Stroke Patients

Stroke is a leading cause of long-term disability, with 30-60% of survivors remaining unable to use their affected arms after discharge. Existing rehabilitation approaches such as motor imagery, robotic assistance, and neuromodulation have shown limited effectiveness for hand motor recovery. The Lifescapes system is a novel EEG-based brain-computer interface that combines motor imagery practice, biofeedback, neuromuscular electrical stimulation, and robotic assistance to help post-stroke patients with severe hand paralysis. A recent clinical trial in 40 patients demonstrated promising improvements in motor function with the Lifescapes system, supporting its potential as a rehabilitation tool.

This study aims to evaluate whether Lifescapes therapy delivered with reduced therapist supervision can improve upper-limb motor function in stroke patients, and whether such an approach is operationally feasible in the local clinical setting.

32 participants will be recruited from Alexandra Hospital and National University Hospital over 2 years.

Participants must be aged 21-80, have had a stroke between 8 weeks and 5 years before enrolment, and have moderate to severe upper-limb impairment. They must be able to give informed consent and follow instructions. Participants are excluded if they are pregnant, have bilateral stroke, severe finger spasticity (MAS >2), implanted stimulators or pacemakers, recent seizures within 90 days, or any unstable medical conditions.

Participants will complete 16 sessions of Lifescapes BCI training over 4-8 weeks (2-4 sessions per week, approximately 30 minutes each). Therapist assistance will be progressively reduced based on each participant's ability, though a therapist remains present throughout. Each Lifescapes session is followed by a 30-minute GRASP session, a standardised self-directed arm and hand exercise programme prescribed by an occupational therapist.

Participants will attend up to 21 visits over 5-6 months. Outcomes are assessed at 6 timepoints: pre-baseline (2-4 weeks before starting), baseline, after the 8th session, after the 16th session, and at 1-month and 3-month follow-up (the latter optional). Outcome measures include the Fugl-Meyer Assessment for the upper extremity (FMA-UE), Action Research Arm Test (ARAT), grip and pinch strength, Modified Ashworth Scale (MAS), Motor Activity Log-14 (MAL-14), EQ-5D-5L quality of life measure, and optional TMS measurement of corticospinal excitability.

Panoramica dello studio

Stato

Non ancora reclutamento

Condizioni

Intervento / Trattamento

Descrizione dettagliata

Background

Stroke is a leading cause of adult long-term disability, with 30-60% of stroke survivors remaining unable to use their affected arms after discharge. While many interventional approaches have been tested - including motor imagery, robotic movement assistance, and neuromodulation - therapeutic efficacy remains limited for hand motor function. The Lifescapes system is a novel EEG-based brain-computer interface (BCI) neurofeedback system that facilitates motor imagery practice in post-stroke patients with severe hemiparesis, integrating biofeedback, neuromuscular electrical stimulation (NMES), and robot-aided sensorimotor stimulation. By triggering NMES and robotic assistance contingent on sensorimotor rhythm event-related desynchronisation (SMR-ERD) magnitude, the system enables voluntary modulation of endogenous sensorimotor activities in the ipsilesional hemisphere. A recent RCT in 40 chronic post-stroke hemiplegic patients demonstrated a significant between-group difference in Fugl-Meyer Assessment scores in favour of the Lifescapes group, supporting its potential as an adjunctive rehabilitation approach.

Study Objectives

The primary objective is to evaluate the effectiveness of Lifescapes therapy with reduced therapist supervision in improving upper-limb motor function in sub-acute and chronic stroke patients with moderate to severe upper limb paresis. The secondary objective is to evaluate the operational feasibility of Lifescapes with reduced therapist supervision in the local context. It is hypothesised that Lifescapes therapy with reduced therapist supervision is feasible in this study population and will quantitatively improve hand motor function.

Study Design

This is a single-arm, prospective study to evaluate the real-world effectiveness and feasibility of Lifescapes with reduced therapist supervision for post-stroke upper-limb rehabilitation. 32 subjects will be recruited from Alexandra Hospital (AH) and National University Hospital (NUH) over an estimated study duration of 2 years.

Participants

Inclusion criteria are: age 21-80 years; first-ever or recurrent ischemic or haemorrhagic stroke; stroke onset between 8 weeks and 5 years prior to enrolment; moderate to severe unilateral upper-limb motor impairment defined as a baseline FMA-UE score <47 and Manual Muscle Testing (MMT) of finger extensor ≤2; ability to provide informed consent and follow verbal instructions; and sufficient visual acuity to scan a full computer screen.

Exclusion criteria include: pregnant or breastfeeding women; bilateral stroke; Modified Ashworth Scale (MAS) of finger flexors >2; use of a pacemaker or other implanted stimulators; history of seizures within 90 days before enrolment; inability to record EEG due to skin status or skull deformity; sensorimotor disturbance due to causes other than stroke; and medically unstable or uncontrolled conditions that may compromise safety or the ability to complete scheduled visits.

Intervention

Eligible subjects will undergo 16 sessions of MI-BCI training with NMES and robotic movement assistance using the paralysed hand through the Lifescapes device. The intervention course must be completed within 4-8 weeks from the first to the last session, at a target frequency of 2-4 sessions per week. Therapist assistance during each Lifescapes session will be reduced progressively according to individual ability, though a therapist will remain present throughout in case assistance is needed. Each session is approximately 30 minutes.

Following each Lifescapes session, participants will complete a standardised occupational therapy programme - GRASP (Graded Repetitive Arm Supplementary Program) - supervised by a trained research staff member. All occupational tasks will be selected from the GRASP task pool and prescribed by an occupational therapist. Each GRASP session will take approximately 30 minutes.

Study Visits and Assessments

There will be up to 21 study visits over 5-6 months, comprising 16 intervention sessions and 6 rounds of assessment at the following timepoints: 2-4 weeks before the first Lifescapes session (pre-baseline), before the first session (baseline), after the 8th session (interim), after the 16th session (post), 1 month after the 16th session (1-month follow-up), and 3 months after the 16th session (3-month follow-up, optional).

Outcome Measures

Clinical outcomes assessed at each timepoint include: Upper Extremity Fugl-Meyer Assessment (FMA-UE); Action Research Arm Test (ARAT); grip and pinch strength measured by dynamometer; Modified Ashworth Scale (MAS) of the affected upper limb muscles; Motor Activity Log-14 (MAL-14); EQ-5D-5L; and corticospinal excitability measurement by TMS (optional).

Tipo di studio

Interventistico

Iscrizione (Stimato)

32

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

  • Adulto
  • Adulto più anziano

Accetta volontari sani

No

Descrizione

Inclusion Criteria:

  1. Age 21-80 years old;
  2. First-ever or recurrent ischemic or haemorrhagic stroke;
  3. Stroke onset between 8 weeks and 5 years prior to enrolment;
  4. Moderate to severe unilateral upper-limb motor impairment following stroke, defined as a baseline upper-extremity Fugal-Meyer Assessment (FMA-UE) score <47, and Manual Muscle Testing (MMT) of finger extensor ≤2;
  5. Being able to provide informed consent, understand and follow verbal instructions.
  6. Having sufficient visual acuity to scan full computer screen.

Exclusion Criteria:

  1. Pregnant or breastfeeding women;
  2. Bilateral stroke;
  3. Modified Ashworth Scale (MAS) of finger flexors >2;
  4. Use of a pacemaker or of other implanted stimulators;
  5. History of seizures within 90 days before enrolment;
  6. Impossible to record EEG because of skin status or skull deformity;
  7. Sensorimotor disturbance due to other causes other than stroke;
  8. Medically unstable or uncontrolled conditions that may compromise safety or the ability to complete scheduled visits.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: N / A
  • Modello interventistico: Assegnazione di gruppo singolo
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: MI-BCI training with NMES and robotic movement assistance
Eligible subjects will undergo 16 sessions of MI-BCI training with NMES and robotic movement assistance using the paralyzed hand through the Lifescapes device.
Lifescapes device is an EEG-based brain-computer-interface (BCI) neurofeedback system. It was developed to facilitate motor imagery (MI) practice in post-stroke patients with severe hemiparesis who are unable to perform voluntary finger extension, serving as a substitute for actual movement exercise. The system comprises 4 components: standard medical treatments with motor imagery (3), biofeedback (4), neuromuscular electrical stimulation (NMES) to paretic muscles (5), and robot-aided sensorimotor stimulation (6). By integrating these components, the EEG-based BCI system enables voluntary modulation of endogenous sensorimotor activities in the ipsilesional hemisphere by triggering the NMES and robotic device contingent on the sensorimotor rhythm event-related desynchronization (SMR-ERD) magnitude.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Upper Extremity Fugal-MeyerFugl-Meyer Assessment (FMA-UE)
Lasso di tempo: Week 0 (Pre-baseline assessment)
FMA-UE is designed to assess motor functioning, balance, sensation and joint functioning in patients with post-stroke hemiplegia. It is applied clinically and in research to determine disease severity, describe motor recovery, and to plan and assess treat. Scores range from 0 to 66, with higher scores indicating better motor function.
Week 0 (Pre-baseline assessment)
Upper Extremity Fugal-MeyerFugl-Meyer Assessment (FMA-UE)
Lasso di tempo: Week 2 (baseline assessment)
FMA-UE is designed to assess motor functioning, balance, sensation and joint functioning in patients with post-stroke hemiplegia. It is applied clinically and in research to determine disease severity, describe motor recovery, and to plan and assess treat. Scores range from 0 to 66, with higher scores indicating better motor function.
Week 2 (baseline assessment)
Upper Extremity Fugal-MeyerFugl-Meyer Assessment (FMA-UE)
Lasso di tempo: Week 5 (Interim-intervention assessment)
FMA-UE is designed to assess motor functioning, balance, sensation and joint functioning in patients with post-stroke hemiplegia. It is applied clinically and in research to determine disease severity, describe motor recovery, and to plan and assess treat. Scores range from 0 to 66, with higher scores indicating better motor function.
Week 5 (Interim-intervention assessment)
Upper Extremity Fugal-MeyerFugl-Meyer Assessment (FMA-UE)
Lasso di tempo: Week 8 (Post-intervention assessment)
FMA-UE is designed to assess motor functioning, balance, sensation and joint functioning in patients with post-stroke hemiplegia. It is applied clinically and in research to determine disease severity, describe motor recovery, and to plan and assess treat. Scores range from 0 to 66, with higher scores indicating better motor function.
Week 8 (Post-intervention assessment)
Upper Extremity Fugal-MeyerFugl-Meyer Assessment (FMA-UE)
Lasso di tempo: Week12 (1 month after the intervention)
FMA-UE is designed to assess motor functioning, balance, sensation and joint functioning in patients with post-stroke hemiplegia. It is applied clinically and in research to determine disease severity, describe motor recovery, and to plan and assess treat. Scores range from 0 to 66, with higher scores indicating better motor function.
Week12 (1 month after the intervention)
Upper Extremity Fugal-MeyerFugl-Meyer Assessment (FMA-UE)
Lasso di tempo: Week 20 (3 months after the intervention)
FMA-UE is designed to assess motor functioning, balance, sensation and joint functioning in patients with post-stroke hemiplegia. It is applied clinically and in research to determine disease severity, describe motor recovery, and to plan and assess treat. Scores range from 0 to 66, with higher scores indicating better motor function.
Week 20 (3 months after the intervention)

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Action Research Arm Test (ARAT)
Lasso di tempo: Week 0 (Pre-baseline assessment)
It evaluates UL motor function and status in standardized format using 19 tests of upper limb motor function across 4 subsets: grasp, pinch, grip, and gross movement, both distally and proximally, following a stroke. The ARAT has a maximum score of 57, with scores ranging from 0 to 57, where higher scores indicate better upper limb function.
Week 0 (Pre-baseline assessment)
Action Research Arm Test (ARAT)
Lasso di tempo: Week 2 (baseline assessment)
It evaluates UL motor function and status in standardized format using 19 tests of upper limb motor function across 4 subsets: grasp, pinch, grip, and gross movement, both distally and proximally, following a stroke. The ARAT has a maximum score of 57, with scores ranging from 0 to 57, where higher scores indicate better upper limb function.
Week 2 (baseline assessment)
Action Research Arm Test (ARAT)
Lasso di tempo: Week 5 (Interim-intervention assessment)
It evaluates UL motor function and status in standardized format using 19 tests of upper limb motor function across 4 subsets: grasp, pinch, grip, and gross movement, both distally and proximally, following a stroke. The ARAT has a maximum score of 57, with scores ranging from 0 to 57, where higher scores indicate better upper limb function.
Week 5 (Interim-intervention assessment)
Action Research Arm Test (ARAT)
Lasso di tempo: Week 8 (Post-intervention assessment)
It evaluates UL motor function and status in standardized format using 19 tests of upper limb motor function across 4 subsets: grasp, pinch, grip, and gross movement, both distally and proximally, following a stroke. The ARAT has a maximum score of 57, with scores ranging from 0 to 57, where higher scores indicate better upper limb function.
Week 8 (Post-intervention assessment)
Action Research Arm Test (ARAT)
Lasso di tempo: Week12 (1 month after the intervention)
It evaluates UL motor function and status in standardized format using 19 tests of upper limb motor function across 4 subsets: grasp, pinch, grip, and gross movement, both distally and proximally, following a stroke. The ARAT has a maximum score of 57, with scores ranging from 0 to 57, where higher scores indicate better upper limb function.
Week12 (1 month after the intervention)
Action Research Arm Test (ARAT)
Lasso di tempo: Week 20 (3 months after the intervention)
It evaluates UL motor function and status in standardized format using 19 tests of upper limb motor function across 4 subsets: grasp, pinch, grip, and gross movement, both distally and proximally, following a stroke. The ARAT has a maximum score of 57, with scores ranging from 0 to 57, where higher scores indicate better upper limb function.
Week 20 (3 months after the intervention)
Grip and pinch strength
Lasso di tempo: Week 0 (Pre-baseline assessment)
Grip and pinch strength will be measured using a hand dynamometer. Grip strength is assessed by asking the participant to squeeze the dynamometer as hard as possible, while pinch strength measures the force exerted between the thumb and fingers. Results are recorded in kilograms or pounds of force. These measures provide an objective assessment of hand and forearm muscle strength, and will be used to track changes in upper limb strength over the course of the study.
Week 0 (Pre-baseline assessment)
Grip and pinch strength
Lasso di tempo: Week 2 (baseline assessment)
Grip and pinch strength will be measured using a hand dynamometer. Grip strength is assessed by asking the participant to squeeze the dynamometer as hard as possible, while pinch strength measures the force exerted between the thumb and fingers. Results are recorded in kilograms or pounds of force. These measures provide an objective assessment of hand and forearm muscle strength, and will be used to track changes in upper limb strength over the course of the study.
Week 2 (baseline assessment)
Grip and pinch strength
Lasso di tempo: Week 5 (Interim-intervention assessment)
Grip and pinch strength will be measured using a hand dynamometer. Grip strength is assessed by asking the participant to squeeze the dynamometer as hard as possible, while pinch strength measures the force exerted between the thumb and fingers. Results are recorded in kilograms or pounds of force. These measures provide an objective assessment of hand and forearm muscle strength, and will be used to track changes in upper limb strength over the course of the study.
Week 5 (Interim-intervention assessment)
Grip and pinch strength
Lasso di tempo: Week 8 (Post-intervention assessment)
Grip and pinch strength will be measured using a hand dynamometer. Grip strength is assessed by asking the participant to squeeze the dynamometer as hard as possible, while pinch strength measures the force exerted between the thumb and fingers. Results are recorded in kilograms or pounds of force. These measures provide an objective assessment of hand and forearm muscle strength, and will be used to track changes in upper limb strength over the course of the study.
Week 8 (Post-intervention assessment)
Grip and pinch strength
Lasso di tempo: Week12 (1 month after the intervention)
Grip and pinch strength will be measured using a hand dynamometer. Grip strength is assessed by asking the participant to squeeze the dynamometer as hard as possible, while pinch strength measures the force exerted between the thumb and fingers. Results are recorded in kilograms or pounds of force. These measures provide an objective assessment of hand and forearm muscle strength, and will be used to track changes in upper limb strength over the course of the study.
Week12 (1 month after the intervention)
Grip and pinch strength
Lasso di tempo: Week 20 (3 months after the intervention)
Grip and pinch strength will be measured using a hand dynamometer. Grip strength is assessed by asking the participant to squeeze the dynamometer as hard as possible, while pinch strength measures the force exerted between the thumb and fingers. Results are recorded in kilograms or pounds of force. These measures provide an objective assessment of hand and forearm muscle strength, and will be used to track changes in upper limb strength over the course of the study.
Week 20 (3 months after the intervention)
Modified Ashworth Scale (MAS)
Lasso di tempo: Week 0 (Pre-baseline assessment)
Modified Tardieu Scale is to measure if there is spasticity present in a person's muscle and its response to movement. It will be measured for upper limb muslces. A large difference between R1 and R2 suggests a large dynamic component with a greater capacity for change or improvement. A small difference between R1 and R2 suggests a predominantly fixed contracture in the muscle with a poorer capacity for change.
Week 0 (Pre-baseline assessment)
Modified Ashworth Scale (MAS)
Lasso di tempo: Week 2 (baseline assessment)
Modified Tardieu Scale is to measure if there is spasticity present in a person's muscle and its response to movement. It will be measured for upper limb muslces. A large difference between R1 and R2 suggests a large dynamic component with a greater capacity for change or improvement. A small difference between R1 and R2 suggests a predominantly fixed contracture in the muscle with a poorer capacity for change.
Week 2 (baseline assessment)
Modified Ashworth Scale (MAS)
Lasso di tempo: Week 5 (Interim-intervention assessment)
Modified Tardieu Scale is to measure if there is spasticity present in a person's muscle and its response to movement. It will be measured for upper limb muslces. A large difference between R1 and R2 suggests a large dynamic component with a greater capacity for change or improvement. A small difference between R1 and R2 suggests a predominantly fixed contracture in the muscle with a poorer capacity for change.
Week 5 (Interim-intervention assessment)
Modified Ashworth Scale (MAS)
Lasso di tempo: Week 8 (Post-intervention assessment)
Modified Tardieu Scale is to measure if there is spasticity present in a person's muscle and its response to movement. It will be measured for upper limb muslces. A large difference between R1 and R2 suggests a large dynamic component with a greater capacity for change or improvement. A small difference between R1 and R2 suggests a predominantly fixed contracture in the muscle with a poorer capacity for change.
Week 8 (Post-intervention assessment)
Motor Activity Log-14 (MAL-14)
Lasso di tempo: Week 12 (1 month after the intervention)
The Motor Activity Log-14 (MAL-14) consists of 14 items rated on two subscales - the Amount of Use (AOU) and Quality of Movement (QOM) scales. Each item is rated from 0 to 5, giving a total score range of 0 to 5 for each subscale, where higher scores indicate greater amount of use and better quality of movement of the affected arm in daily activities.
Week 12 (1 month after the intervention)
Motor Activity Log-14 (MAL-14)
Lasso di tempo: Week 20 (3 months after the intervention)
The Motor Activity Log-14 (MAL-14) consists of 14 items rated on two subscales - the Amount of Use (AOU) and Quality of Movement (QOM) scales. Each item is rated from 0 to 5, giving a total score range of 0 to 5 for each subscale, where higher scores indicate greater amount of use and better quality of movement of the affected arm in daily activities.
Week 20 (3 months after the intervention)
EQ5D
Lasso di tempo: Week 0 (Pre-baseline assessment)
EQ5D is an instrument which evaluates the generic quality of life developed in Europe and widely used. It has one question for each of the five dimensions that include mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, each dimension scored from 1 to 5, the higher score indicates worse performance.
Week 0 (Pre-baseline assessment)
EQ5D
Lasso di tempo: Week 2 (baseline assessment)
EQ5D is an instrument which evaluates the generic quality of life developed in Europe and widely used. It has one question for each of the five dimensions that include mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, each dimension scored from 1 to 5, the higher score indicates worse performance.
Week 2 (baseline assessment)
EQ5D
Lasso di tempo: Week 5 (Interim-intervention assessment)
EQ5D is an instrument which evaluates the generic quality of life developed in Europe and widely used. It has one question for each of the five dimensions that include mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, each dimension scored from 1 to 5, the higher score indicates worse performance.
Week 5 (Interim-intervention assessment)
EQ5D
Lasso di tempo: Week 8 (Post-intervention assessment)
EQ5D is an instrument which evaluates the generic quality of life developed in Europe and widely used. It has one question for each of the five dimensions that include mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, each dimension scored from 1 to 5, the higher score indicates worse performance.
Week 8 (Post-intervention assessment)
EQ5D
Lasso di tempo: Week12 (1 month after the intervention)
EQ5D is an instrument which evaluates the generic quality of life developed in Europe and widely used. It has one question for each of the five dimensions that include mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, each dimension scored from 1 to 5, the higher score indicates worse performance.
Week12 (1 month after the intervention)
EQ5D
Lasso di tempo: Week 20 (3 months after the intervention)
EQ5D is an instrument which evaluates the generic quality of life developed in Europe and widely used. It has one question for each of the five dimensions that include mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, each dimension scored from 1 to 5, the higher score indicates worse performance.
Week 20 (3 months after the intervention)
Corticospinal Excitability measurement by TMS- Motor threshold
Lasso di tempo: Week 0 (Pre-baseline assessment)
It is a non-invasive technique used to assess how readily the brain can activate the muscles. A magnetic coil is placed over the scalp above the motor area of the brain, and a brief magnetic pulse is delivered to stimulate the nerve pathways that connect the brain to the muscles (the corticospinal tract). The smallest pulse intensity needed to produce a visible or measurable muscle twitch is called the "motor threshold." A lower motor threshold means the brain-to-muscle pathway is more excitable or responsive, which is generally associated with better motor function.
Week 0 (Pre-baseline assessment)
Corticospinal Excitability measurement by TMS- Motor threshold
Lasso di tempo: Week 2 (baseline assessment)
It is a non-invasive technique used to assess how readily the brain can activate the muscles. A magnetic coil is placed over the scalp above the motor area of the brain, and a brief magnetic pulse is delivered to stimulate the nerve pathways that connect the brain to the muscles (the corticospinal tract). The smallest pulse intensity needed to produce a visible or measurable muscle twitch is called the "motor threshold." A lower motor threshold means the brain-to-muscle pathway is more excitable or responsive, which is generally associated with better motor function.
Week 2 (baseline assessment)
Corticospinal Excitability measurement by TMS- Motor threshold
Lasso di tempo: Week 5 (Interim-intervention assessment)
It is a non-invasive technique used to assess how readily the brain can activate the muscles. A magnetic coil is placed over the scalp above the motor area of the brain, and a brief magnetic pulse is delivered to stimulate the nerve pathways that connect the brain to the muscles (the corticospinal tract). The smallest pulse intensity needed to produce a visible or measurable muscle twitch is called the "motor threshold." A lower motor threshold means the brain-to-muscle pathway is more excitable or responsive, which is generally associated with better motor function.
Week 5 (Interim-intervention assessment)
Corticospinal Excitability measurement by TMS- Motor threshold
Lasso di tempo: Week 8 (Post-intervention assessment)
It is a non-invasive technique used to assess how readily the brain can activate the muscles. A magnetic coil is placed over the scalp above the motor area of the brain, and a brief magnetic pulse is delivered to stimulate the nerve pathways that connect the brain to the muscles (the corticospinal tract). The smallest pulse intensity needed to produce a visible or measurable muscle twitch is called the "motor threshold." A lower motor threshold means the brain-to-muscle pathway is more excitable or responsive, which is generally associated with better motor function.
Week 8 (Post-intervention assessment)
Corticospinal Excitability measurement by TMS- Motor threshold
Lasso di tempo: Week12 (1 month after the intervention)
It is a non-invasive technique used to assess how readily the brain can activate the muscles. A magnetic coil is placed over the scalp above the motor area of the brain, and a brief magnetic pulse is delivered to stimulate the nerve pathways that connect the brain to the muscles (the corticospinal tract). The smallest pulse intensity needed to produce a visible or measurable muscle twitch is called the "motor threshold." A lower motor threshold means the brain-to-muscle pathway is more excitable or responsive, which is generally associated with better motor function.
Week12 (1 month after the intervention)
Corticospinal Excitability measurement by TMS- Motor threshold
Lasso di tempo: Week 20 (3 months after the intervention)
It is a non-invasive technique used to assess how readily the brain can activate the muscles. A magnetic coil is placed over the scalp above the motor area of the brain, and a brief magnetic pulse is delivered to stimulate the nerve pathways that connect the brain to the muscles (the corticospinal tract). The smallest pulse intensity needed to produce a visible or measurable muscle twitch is called the "motor threshold." A lower motor threshold means the brain-to-muscle pathway is more excitable or responsive, which is generally associated with better motor function.
Week 20 (3 months after the intervention)
System Usability Scale (SUS)
Lasso di tempo: Week 8 (Post-intervention assessment)
SUS is a validated, 10-item questionnaire. Each item is rated on a 5-point Likert scale ranging from strongly disagree to strongly agree.
Week 8 (Post-intervention assessment)
MoCA
Lasso di tempo: Week 0 (Pre-baseline assessment)
It is a screening tool to detect mild cognitive impairment. It assesses several aspects of cognitive function, including memory, attention, language, and orientation. Scores range from 0 to 30, with a score of 26 or above generally considered normal. A lower score may indicate the presence of cognitive difficulties.
Week 0 (Pre-baseline assessment)

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Collaboratori

Investigatori

  • Investigatore principale: Peijing Su, MBBS, NUH

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

1 ottobre 2026

Completamento primario (Stimato)

30 settembre 2027

Completamento dello studio (Stimato)

30 settembre 2027

Date di iscrizione allo studio

Primo inviato

20 agosto 2026

Primo inviato che soddisfa i criteri di controllo qualità

20 agosto 2026

Primo Inserito (Effettivo)

25 agosto 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

25 agosto 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

20 agosto 2026

Ultimo verificato

1 agosto 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • 2026-0446

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .